Shares of Moderna Inc. mRNA,
rose 1.3% in premarket trading on Monday after the company said it plans to launch new development programs using its mRNA technology that will focus on developing seasonal flu, HIV and Nipah virus vaccines. This follows the success of its COVID-19 mRNA vaccine, which is one of two vaccines to be licensed so far in the US CEO, Moderna also said it intends to expand its respiratory syncytial virus to include adults. older and intends to test different vaccines. combinations fighting influenza, COVID-19, RSV and human metapneumovirus. “The unique challenging year of 2020 for the whole society has proved to be an extraordinary period of proof of the concept for Moderna,” CEO Stéphane Bancel said in a press release. As part of its corporate update, Moderna said it had about $ 5.2 billion in cash as of Dec. 31, compared to $ 1.2 billion in cash it had at the same time a year ago and expects generate revenue of at least $ 11.7 billion. in 2021 for the COVID-19 vaccine based on advance purchase agreements. Moderna shares have risen 489.1% in the last year, while the S&P 500 SPX,
it is increasing by 19.7%.